Freestyle Libre is a product to monitor blood glucose levels without taking blood from the body. Usability study shows patients who used the product
Positive results from the 52-week FREEDOM-2 clinical trial of ITCA 650, an injection-free GLP-1 receptor agonist was presented by Intarcia Therapeutics, Inc to ADA on June 12th, 2016. A patient can get uninterrupted and consistent exenatide medication from osmotic mini-pump that will be placed under the skin. With some type 2 diabetes (T2D) patients, metformin tablet may not able reduce HbA1c levels and body weight. Trials of ITCA 650 with those patients got better results compared with Januvia in reducing HbA1c levels and body weight. The drug was successful in trials. Dr. Julio Rosenstock MD was the lead investigator of the study.
An advisory panel to FDA concluded that diabetes drug Jardiance (by Eli Lilly & Co and Boehringer Ingelheim) cuts cardiovascular death. Jardiance was approved in 2014 to lower blood sugar levels in type 2 diabetes (T2D) patients. Now manufacturers are seeking approval of the drug for the treatment of risk of death from heart attacks and strokes.
In a one year study, researchers gave invokana as add-on therapy to metformin in patients with type 2 diabetes (T2D). The study found that body weight and blood pressure were reduced and glycemic control was improved in the patients. Researchers presented the study findings to AACE.
Medtronic developed MiniMed 670G, an artificial pancreas and filed for US approval. The device eliminates routine sugar control exercises like finger pricks and insulin injections. The device helps both type 1 diabetes (T1D) and type 2 diabetes (T2D) patients who need insulin injections to control blood sugar levels. The device is of size smartphone, connects insulin pump and glucose monitor without using a cable or wire. The equipment remains outside the body and can take place of patient's malfunctioning organ that produces insulin which converts blood sugar to energy. The new artificial pancreas device administers or withholds microdoses of insulin to keep type 1 diabetes (T1D) patient in predetermined target range after checking blood sugar levels for every five minutes.
Toujeo manufactured by Sanofi is a long-acting insulin for type 1 (T1D) and type ii diabetes (T2D) patients. Sanofi recently released the toujeo drug evaluation reports with type 2 diabetes (T2D) patients and presented them in 76th ADA scientific sessions in New Orleans. The reports indicate that the switching to toujeo from another basal insulin usage drug was successful.
VM BioPharma is the US division of South Korean based company ViroMed Co., Ltd. VM202 is a proprietary DNA based BioPharmaceutical intended for the patients with painful diabetic peripheral neuropathy (DPN). High glucose levels in the blood damage nerve (mostly in lower limbs) and give sudden and severe pain and are called DPN. Currently, there is no medications or treatments available for DPN and affects 5 to 20 percent of diabetes patients. Maintaining blood sugar levels is the only option left to control DPN. The cell produces human hepatocyte growth factor (HGF) proteins when drug VM202 is injected into the muscle and induces the formation of new blood vessels. Drug VM202 promotes microvasculature and regenerate nerve cells. VM BioPharma announced that they initiated phase 3 clinical study, first pivotal gene therapy for the evaluation of the VM202 drug. Significant and rapid reduction DPN pain was found during phase 2 trial of the VM202 drug. Investigator of the Phase 3 study is Dr. Jack Kessler M.D. He is a professor in Neurology, Feinberg School of Medicine, Northwestern University.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.